Abstract: ObjectiveTo establish of the criteria of nedaplatin for drug use evaluation (DUE), and provide new evidence for prescription evaluation. MethodsBased on the instruction of nedaplatin, as well as the Guideline of Prescription Review for Antitumor Agents, the Principles of Clinical Application of Antitumor Agents (Draft) by Ministry of Health, the Standards of Drug Use for Chemotherapy and relevant literatures about clinical use of nedaplatin, a standard draft about nedaplatin DUE was established which focused on effectiveness, safety, compliance and drug economy. Then, experts from the Pharmacy Management and Pharmacotherapeutics Committee of our hospital were consulted. ResultsComprehensive standards of nadaplatin DUE were established from the aspects of effectiveness, safety, compliance and drug economy. ConclusionThe established standards of nedaplatin DUE can provide new approaches for rational evaluation in medical institutions.